Quadrant Biosciences

Top Deal
BETA

World's First Saliva Test for Autism - Available in Clinics Now

Analytics

Raised to Date: $1,004,649

Aggregate Commitments $
Platform

Wefunder

Start Date

02/02/2020

Close Date

08/15/2020

Min. Goal

$50,000

Max. Goal

$15,000,000

Min. Investment

$501

Security Type

Equity - Common

Funding Type

RegA+

Valuation

$266,000,000

Weekly Commitments $
Status
Funded
Reporting Date

08/31/2020

Days Remaining
Funded
% of Min. Goal

2,009%

% of Max. Goal

7%

Likelihood of Max
Funded
Avg. Daily Raise

$5,152

# of Investors

976

Momentum
Funded
Location

Syracuse, New York

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Quadrant Biosciences, with a pre-money valuation of $266 million, is raising funds on Wefunder through Reg A+ crowdfunding. The company has launched the world’s first saliva test for autism and is developing a pipeline of products, including tests for schizophrenia, anorexia nervosa, concussion, and Parkinson’s disease. The test for autism, The Clarifi ASD Test, is a game-changer in autism diagnosis and indicates the probability of a child having autism spectrum disorder. Quadrant Biosciences was founded by Richard Uhlig and has raised over $30 million in previous rounds of financing. The current round of crowdfunding has a minimum goal of $50,000 and a maximum goal of $15,000,000, and the proceeds will be used in developing more tests. Quadrant Biosciences has multiple international research partnerships and is working on developing a rapid saliva test for COVID-19.

Balance Sheet

Cash and Cash Equivalents

$3,107,794

Investment Securities

$0

Total Investments

$0

Accounts and Notes Receivable

$116,383

Loans

$0

Property, Plant and Equipment (PP&E)

$38,292

Property and Equipment

$0

Total Assets

$9,846,764

Accounts Payable & Accrued Liabilities

$145,712

Policy Liabilities and Accruals

$0

Deposits

$0

Long Term Debt

$5,304,909

Total Liabilities

$5,947,496

Total Stockholders' Equity

$3,899,268

Total Liabilities and Equity

$9,846,764

Statement of Comprehensive Income Information

Total Revenues

$343,449

Total Interest Income

$0

Costs & Expenses Applicable to Rev

$208,446

Total Interest Expenses

$0

Depreciation and Amortization

$11,331

Net Income

$-4,840,262

Earnings Per Share - Basic

$0

Earnings Per Share - Diluted

$0

Auditor: Dannible & McKee, LLP
Summary of Crowdfunding Raises
Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
02/18/2021 Wefunder $0 $411,608 Convertible Note Confirmed Closed RegCF
08/15/2020 Wefunder $266,000,000 $1,004,649 Equity - Common Confirmed Closed RegA+

Analyst Report

Top Deal
Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.
Other Deals

MedVector on StartEngine

The COVID-19 pandemic has grown the telehealth industry exponentially. A recent study of U.S medical specialists found that

Crowd
Phoenix PharmaLabs on Netcapital

In the years before the world’s current COVID-19 crisis, America in particular faced a deadly and persistent threat…

Crowd
C-Reveal Therapeutics on NetCapital

Cancer is the great, mysterious killer of medical science. As of January 2019, there were an

Crowd
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Quadrant Biosciences on Wefunder
Follow company
Follow Quadrant Biosciences on Wefunder